{
    "organizations": [],
    "uuid": "83452d21110a172ca28f0172c1e062c37fa33592",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vbl-therapeutics-announces-top-lin/brief-vbl-therapeutics-announces-top-line-results-from-pivotal-phase-3-globe-study-in-patients-with-recurrent-glioblastoma-idUSFWN1QQ0AJ",
    "ord_in_thread": 0,
    "title": "BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Vascular Biogenics Ltd:\n* VBL THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 GLOBE STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA\n* VASCULAR BIOGENICS LTD - ‍STUDY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF OVERALL SURVIVAL​\n* VASCULAR BIOGENICS LTD - PHASE 3 GLOBE STUDY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF OVERALL SURVIVAL​\n* VASCULAR BIOGENICS LTD - ‍BELIEVE THAT VB-111 MAY STILL HOLD PROMISE FOR OTHER INDICATIONS CO CURRENTLY OR MAY STUDY IN FUTURE​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-08T19:18:00.000+02:00",
    "crawled": "2018-03-08T13:43:05.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "vascular",
        "biogenics",
        "ltd",
        "vbl",
        "therapeutic",
        "announces",
        "result",
        "pivotal",
        "phase",
        "globe",
        "study",
        "patient",
        "recurrent",
        "glioblastoma",
        "vascular",
        "biogenics",
        "ltd",
        "meet",
        "primary",
        "endpoint",
        "overall",
        "vascular",
        "biogenics",
        "ltd",
        "phase",
        "globe",
        "study",
        "meet",
        "primary",
        "endpoint",
        "overall",
        "vascular",
        "biogenics",
        "ltd",
        "may",
        "still",
        "hold",
        "promise",
        "indication",
        "co",
        "currently",
        "may",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}